Climate Change Data

Royalty Pharma plc

Climate Impact & Sustainability Data (2021, 2022, 2023)

Reporting Period: 2021

Environmental Metrics

Total Carbon Emissions:315,679 tCO2e (Scope 3, Category 15)
Scope 1 Emissions:113 tCO2e
Scope 2 Emissions:113 tCO2e
Scope 3 Emissions:315,679 tCO2e (Category 15)

ESG Focus Areas

  • Governance
  • Employee well-being
  • Environmental sustainability
  • Responsible investment

Environmental Achievements

  • Achieved ENERGY STAR certification and WELL designation for New York headquarters
  • Encouraging green building certification at headquarters
  • Reimbursing Citi Bike memberships for employees to encourage carbon-free commutes
  • Installing water fountains to support reusable water bottles

Social Achievements

  • Launched employee learning and development program with 100% of initial participants finding it useful
  • Offered 16 weeks of parental leave for the primary caregiver and 4 weeks for the secondary caregiver
  • Maintained a voluntary and involuntary turnover rate of 3.4% each in 2021
  • 100% of employees completed annual compliance training in 2021
  • Donated $5.3 million to support COVID-19 research between 2020 and 2021
  • Donated over $700,000 to six organizations in 2021

Governance Achievements

  • Completed a materiality assessment in 2022, consulting investors, employees, senior management, and the board of directors
  • Adopted a robust Cybersecurity and Personal Data Breach Policy
  • Implemented a strong compensation recovery (“Clawback”) policy for the Manager and executive officers
  • Adopted proxy voting policies and procedures in accordance with Rule 206(4)-6 of the Investment Advisers Act
  • Implemented a Whistleblower Hotline hosted by an independent third party

Climate Goals & Targets

Short-term Goals:
  • 100% of employees to complete the employee learning and development program

Environmental Challenges

  • Risk of scams and security breaches
  • ESG-related risks associated with portfolio companies
Mitigation Strategies
  • Security measures in place to ensure data security and protection
  • Robust due diligence process for new investments, including ESG and reputational risk assessment
  • Engagement with subject-matter experts and special advisors as needed

Supply Chain Management

Responsible Procurement
  • Royalty Pharma Supplier Code of Conduct

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI, SASB

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:19,610 tCO2e/year (Scope 3 Category 15)
Scope 1 Emissions:
Scope 2 Emissions:
Scope 3 Emissions:19,610 tCO2e/year

ESG Focus Areas

  • Corporate Governance
  • ESG Governance
  • Responsible Investment
  • Access to Health and Medicine
  • Diversity, Equity and Inclusion
  • Human Capital Management

Environmental Achievements

  • Reduced operational footprint through energy-efficient office lighting and water filtration system.
  • Published Greenhouse Gas emissions (GHG) data for 2021 and 2022 with limited assurance from Ernst & Young LLP.

Social Achievements

  • 11.9% headcount growth in 2022 with 5.6% total turnover.
  • Donated and pledged approximately $29 million in 2022 to non-profits focused on health equity and underserved communities.
  • Launched a matching charitable donation program in 2022.
  • Expanded opportunities for employee professional development.
  • Improved the comprehensive benefits offered to employees.

Governance Achievements

  • Conducted first materiality assessment.
  • Improved transparency through publication of ESG fact sheet and 2021 GRI and SASB Summary.
  • 90% of Board is independent.

Climate Goals & Targets

Long-term Goals:
  • Achieve carbon neutrality (timeline not specified).

Environmental Challenges

  • Measuring and reducing Scope 3 emissions.
  • Addressing systemic inequities in healthcare access.
Mitigation Strategies
  • Expanding Scope 3 emissions measurements and creating a framework to reduce impact.
  • Established partnerships with organizations focused on health equity research (e.g., Mount Sinai, Leukemia & Lymphoma Society).

Supply Chain Management

Responsible Procurement
  • Supplier Code of Conduct (addresses ethical and labor concerns).

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI, SASB

Third-party Assurance: Ernst & Young LLP (limited assurance for GHG emissions)

UN Sustainable Development Goals

  • SDG 3 (Good Health and Well-being)

Funding innovation in biopharmaceutical industry and treating diseases.

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:32,002 tCO2e/year
Scope 1 Emissions:N/A
Scope 2 Emissions:N/A
Scope 3 Emissions:32,002 tCO2e/year

ESG Focus Areas

  • Responsible Investment
  • Access to Health and Medicine
  • Diversity, Equity and Inclusion
  • Human Capital Management
  • Corporate Governance

Environmental Achievements

  • Provided online training on sustainability and recycling efforts and procedures.
  • New York City office is Energy Star certified and WELL designated.

Social Achievements

  • Formed a Diversity, Equity and Inclusion (DEI) Task Force.
  • Conducted employee engagement survey.
  • Offered two internship programs.
  • Donated $7.5 million to non-profit organizations.
  • Low employee turnover (6.2% average total turnover past three years).

Governance Achievements

  • Implemented Responsible Investment Policy.
  • Expanded Board of Director Oversight on Sustainability and Responsible Business-Related Topics.
  • Published inaugural Corporate Responsibility Report.
  • 100% of employees certified compliance with Code of Business Conduct and Ethics.
  • 100% of employees completed mandatory ethics training.

Climate Goals & Targets

Environmental Challenges

  • Sustainability and responsible business risks and opportunities extend beyond our immediate operations as they are also manifested in our partners’ businesses.
  • Scope 3 emissions related to portfolio investments are the most material emissions category.
Mitigation Strategies
  • Published Responsible Investment Policy to further formalize robust due diligence process.
  • Incorporated human rights considerations into investment practices.
  • Calculated Scope 3 Category 15 GHG emissions by disaggregating portfolio and applying emission intensity factors.
  • Expanded Scope 3 emissions measurements.

Supply Chain Management

Responsible Procurement
  • Supplier Code of Conduct

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI, SASB

Third-party Assurance: Apex Companies, LLC

UN Sustainable Development Goals

  • SDG 3

Social Bond Framework contributes to SDG 3.